IP Library Granted Patent US 8,409,566
Granted Patent B2
US 8,409,566 · App. 12/367,308 · Granted Apr 2, 2013

Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,409,566
App. No.
12/367,308
Granted
Apr 2, 2013
Kind
B2
Abstract

The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicant's surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

Claims (10)

1. A method of inhibiting the proliferation of a cell within a brain tumor, neuroblastoma or breast tumor that over-expresses SDF-1 (SEQ ID NO: 4) in a subject comprising administering to the subject in which such treatment is desired a therapeutically effective amount of an antibody that specifically binds to SDF-1 (SEQ ID NO:4) and that inhibits SDF-1 binding to CXCR-4 on the tumor cell.

2. The method of claim 1 in which the cell that over-expresses SDF-1 (SEQ ID NO: 4) is malignant.

3. The method of claim 1 in which the subject is a human.

4. The method of claim 1 in which the cell that over-expresses SDF-1 (SEQ ID NO: 4) is within the brain tumor selected from meningioma, or malignant glioma and wherein the administration is into the central nervous system.

5. The method of claim 4 in which the glioma is glioblastoma multiforme.

6. The method of claim 1 in which the antibody is a polyclonal antibody or a monoclonal antibody or antigen binding fragment thereof.

7. The method of claim 1 , wherein the antibody is a chimeric antibody, a single chain antibody, a Fab′, a F(ab′) 2 or a Fab fragment.

8. The method of claim 1 , wherein the antibody is a bispecific antibody.

9. The method of claim 1 , wherein the antibody is conjugated with a label or therapeutic moiety.

10. The method of claim 9 , wherein the label or therapeutic moiety is a radioactive metal ion, a toxin, or a drug.

Assignments (1)
SECURITY AGREEMENT Recorded Apr 18, 2012
From: NORTHWEST BIOTHERAPEUTICS, INC.
To: FOUR M PURCHASERS, LLC
Reel/Frame 028069/0752 →